Neonatal gene therapy is a promising strategy for treating a number of congenital diseases diagnosed shortly after birth as expression of therapeutic proteins during postnatal life may limit the pathologic consequences and result in a potential "cure." Hemophilia A is often complicated by the development of antibodies to recombinant protein resulting in treatment failure. Neonatal administration of vectors may avoid inhibitory antibody formation to factor VIII (FVIII) by taking advantage of immune immaturity. A helper-dependent adenoviral vector expressing human factor VIII was administered i.v. to neonatal hemophilia A knockout mice. Three days later, mice produced high levels of FVIII. Levels declined rapidly with animal growth to 5 wk of age with stable factor VIII expression thereafter to >1 y of age. Decline in factor VIII expression was not related to cell-mediated or humoral responses with lack of development of antibodies to capsid or human factor VIII proteins. Subsequent readministration and augmentation of expression was possible as operational tolerance was established to factor VIII without development of inhibitors; however, protective immunity to adenovirus remained.
immune response | coagulation H emophilia A is an X-linked recessive disease caused by a deficiency of clotting factor VIII (FVIII). FVIII protein, in a complex with factor IX, regulates the conversion of factor X to factor Xa. The deficiency of FVIII results in a marked reduction in this conversion and is characterized by frequent bleeding episodes. The current treatment is the administration of plasmaderived or recombinant human FVIII protein. Complicating therapy in some patients is the development of inhibitory antibodies ("inhibitors") that prevent the function of the activated protein and thus result in a failure of hemostasis. The development of inhibitors occurs in ≈20-25% of patients (1, 2) and is one of the most challenging complications of treatment in persons with hemophilia A, resulting in increased morbidity and cost of care. Although viral vector gene therapy for this disorder was initially met with enthusiasm, the failure of therapy in adult animals due to the development of inhibitory antibodies or neutralizing immune responses has blunted this initial excitement.
A number of reports suggest that there are advantages to initiating gene therapy in the neonatal period (3) (4) (5) (6) (7) (8) . These advantages include the following: (i) early gene expression to avoid the development of irreversible pathology; (ii) administering vector earlier results in greater vector to cell ratio, allowing for less vector administration; (iii) stem and progenitor cells, likely less accessible later in life, may be more easily transduced; and (iv) immune responses may be reduced or absent (7) . A number of animal models have been treated in the neonatal period with encouraging results, including Crigler-Najjar syndrome (9), mucopolysaccharidosis type VII (10) (11) (12) , Pompe disease (13) , and spinal muscular atrophy (14) .
Whereas using neonatal gene therapy for the treatment of secretory proteins in humans may allow for correction of disease during early postnatal development, the challenges of correcting an otherwise newborn mammal and expecting significant correction to remain when adult size is attained are not without significant concern. Although the use of nonintegrating viral vectors may lead to enhanced safety and avoidance of potential oncogenesis that has been detected with other viral vector systems (15) (16) (17) , it invokes further challenges in that transgene expression may not be stable due to vector loss with cytokinesis and animal growth along with an expansion in blood volume and dilution of secreted transgene-encoded proteins. Whereas sustained therapeutic levels may not be achieved with a single administration of vector, if operational immunologic tolerance is established, further administration of vector at a later time may successfully supplement expression. This aspect, gene therapy to induce tolerance for subsequent augmentation, has not been previously explored. Tolerance to vector-associated antigens (i.e., virus) would be unfavorable due to the risk of subsequent exposure to wild-type virus and potential for development of pathology with possible overwhelming viremia and death.
Here we show that with a helper-dependent adenoviral vector (Hd-AV) expressing factor VIII, protein levels of the coagulant result in improvement in the coagulation deficiency and a longterm substantial reduction in bleeding for at least 16 mo of life in FVIII-deficient mice. Operational tolerance to human factor VIII was established and augmentation of expression was possible with a second dose of vector. Importantly, immune tolerance to virusassociated antigens was not established as immunological ignorance was present during the period of viral uncoating.
Results
Tolerability of Virus Administration. Matings of FVB/n hemophilic males (X H Y) and hemophilic females (X H X H ) were set up to produce offspring that were all affected. Previously published data demonstrate that these mice develop antibodies to human factor VIII in adult animals when injected with Hd-AV expressing human FVIII (18) . On the third day of life, mice were i.v. administered 5 × 10 12 viral particles (vp)/kg of Hd-AV expressing B domain-deleted human factor VIII under control of the phosphoenol pyruvate carboxykinase (PEPCK) promoter and ApoE1 enhancer (Hd-AV-FVIII). The woodchuck hepatitis virus postregulatory enhancer (WPRE) was included as was the human growth hormone polyadenylation signal (Fig. 1) . A total of 51 mice were injected with helper-dependent adenovirus on the third day of life. All newborn mice survived the injection as did the vehicle-injected (pharmaceutical grade saline) controls. Survival throughout the studies was high with only a small number of mice dying in the first week of life: Four of 51 injected To whom correspondence should be addressed. E-mail: glipshutz@mednet.ucla.edu.
with Hd-AV-FVIII died (92.2% survival) and 1 of 13 injected with saline died in the first week of life (92.3% survival) [P = not significant (NS)].
Injected mice were weighed frequently to assess weight gain and they demonstrated typical growth ( Fig. 2A) . Alanine aminotransferase levels were examined on the 35th day of life and compared with those of saline-injected controls to assess toxicity. Hd-AVinjected mice demonstrated alanine aminotransferase (ALT) values of 33.0 ± 5.6 IU/mL (n = 6) whereas saline-injected animals demonstrated ALT values of 34.2 ± 6.2 IU/mL (n = 5) (P = 0.74). There was no difference between female and male mice. Human FVIII expression peaked 3 d after the injection [day of life (DOL) 6] at 648.8 ± 124.2% of normal (Fig. 2B) . By day 9, expression was at 309.4 ± 85.0% as animal weight increased from 1.6 ± 0.2 g on DOL 3 to 3.4 ± 0.5 g on DOL 9 ( Fig. 2A) . Further decline was present on DOL 18 with 136.7 ± 13.2% and weight increased to 7.7 ± 0.6 g. By day 21, FVIII expression declined to 46.9 ± 15.2% and at 4 wk, FVIII expression was 5.0 ± 0.6% with a weight of 15.5 ± 1.7 g. Over the subsequent 16 mo, FVIII expression remained stable from 2.3 ± 0.5% to 6.8 ± 1.8% (Fig. 2C ).
Factor VIII Is Functional Resulting in Shortening of Bleeding Time. To assess whether FVIII activity correlated with phenotypic correction in virus-treated mice, bleeding time was analyzed by tail clip assay at 5 wk and at 7 mo after neonatal FVIII knockout mice received Hd-AV-FVIII. Saline-injected wild-type mice (5 wk) were examined for comparison (range 44-56 s) (Fig. 3) . The bleeding time in all Hd-AV-FVIII-injected mice (at 5 wk, range 57-310 s and at 7 mo, range 78-230 s) declined from that of salineadministered knockout mice (>600 s), demonstrating that functional factor VIII is produced and that partial correction of the phenotype is present.
Vector Copy Number Decreases in the First Weeks After Virus Administration. Mice were randomly selected at predetermined time points after injection of Hd-AV-FVIII. Livers were removed and DNA was prepared for nucleic acid analysis. Viral DNA was quantitated by real-time PCR to determine the total copy number per genomic DNA. At least three mice were analyzed at each time point. Vector copy number declined substantially between day 5 and day 30, becoming stable at approximately one copy per hepatocyte from 3 mo to ≥1 y of age (Fig. 4 ).
Antibodies to Helper-Dependent Adenovirus and Human FVIII Do Not
Develop After Neonatal Injection. Antibodies to vector-associated proteins and FVIII were examined after neonatal injection of Hd-AV-FVIII. As adults (5 wk of age), mice were bled and plasma was examined for antibodies against human factor VIII by ELISA. Antibodies to FVIII were not present ( Fig. 5A) in any of the mice tested (n = 5) as they continued to demonstrate expression of FVIII. Plasma was also examined for antibodies against helper-dependent adenoviral capsid proteins. Similarly, all mice demonstrated no antibodies against vector-associated antigens ( 
Augmentation of FVIII Expression Is Possible with a Subsequent
Vector Injection. As corrected mice demonstrate long-term expression of factor VIII at ∼3-7%, we sought to examine if we could augment expression by administering a second postnatal or adult dose of vector to adult animals; control mice, that had been ad- ministered saline on the second day of life, were included. Mice were administered 5 × 10 12 vp/kg of Hd-AV-FVIII i.v. (Fig. 6 ) as both factor VIII levels and antibody development to vectorassociated antigens were examined. Control adult animals (injected as neonates with saline) had development of FVIII expression to 34.5 ± 18.0% of normal 6 d after administration; concomitant with this was the development of an antibody response to Hd-AV and FVIII ( Fig. 7 A and B) and loss of factor VIII expression. However, the neonatally injected Hd-AV-FVIII animals demonstrated different findings. Factor VIII expression after supplemental adult vector administration resulted in augmentation from basal expression of 5%, to as high as 70% early, with persistence to 48% subsequently (Fig. 6 ) to at least 3 mo postadministration. Similar to that in control animals, an antibody-mediated response developed to the helper-dependent adenovirus in this group (Fig. 7D) , suggesting that the lack of response at the time of the neonatal administration was due to immunologic ignorance and not tolerance.
Inhibitors Do Not Develop to Subsequent Administration of
Recombinant FVIII or Vector. Control mice that were administered Hd-AV-FVIII only as adults developed antibodies to FVIII shortly after vector administration (Fig. 7A) . However, mice that received Hd-AV-FVIII as neonates and were subsequently readministered vector as adults did not (Fig. 7C) . Taken together, these data demonstrate that tolerance to FVIII in these hemophilic animals has been established.
Discussion
The treatment of patients with severe hemophilia A has improved owing to the availability of FVIII concentrates that are manufactured with improved viral safety, advancement of techniques for performing venipuncture during home treatment, and the widespread adoption of prophylaxis to prevent bleeding episodes (19) (20) (21) . With these advances, however, the development of inhibitors (alloantibodies to FVIII) remains the most challenging complication of treating hemophilia A patients and results in increased morbidity and is a significant economic burden (22) . The risk of inhibitor formation is influenced by the type of FVIII mutation (23) (24) (25) (26) . Inversions, large deletions, and nonsense mutations are associated with the highest risk, likely because the immune system recognizes normal factor VIII protein as a neoantigen (27) . Other factors known to influence the risk of inhibitor development include the severity of hemophilia A, patient ethnicity, intensive factor exposure at the time of surgery, age at first infusion, prophylactic or on-demand treatment regimens, the source of FVIII, and the cumulative number of days of replacement therapy (28) (29) (30) (31) . In addition, numerous studies to develop gene replacement strategies for hemophilia A in both small and large animal models have been complicated by the development of inhibitors (32) (33) (34) (35) .
The ability to correct hemophilia A or alter its phenotype would lessen the burden of disease in these patients. Of equal importance, development of tolerance to factor VIII protein would allow for administration of factor VIII without fear of inhibitor development if gene therapy alone was not sufficient in correcting the bleeding diathesis. In the studies conducted herein we evaluated in mice the efficacy of neonatal administration of a single dose of helper-dependent adenoviral vector expressing human FVIII to correct hemophilia A and examined the immune response to both FVIII and vector-associated antigens with primary injection and with subsequent administration of vector.
Helper-dependent adenoviral vectors are devoid of all viral coding sequences, unlike first-generation vectors. Numerous studies have demonstrated their superiority to first-generation vectors in mediating long-term transgene expression with minimal chronic hepatotoxicity (36) (37) (38) (39) . However, like that of firstgeneration adenoviral vectors, administration results in acute toxicity consistent with activation of an acute inflammatory response characterized by elevation in liver enzymes and proinflammatory cytokines and chemokines related to viral capsid proteins (40) . The results from the studies conducted herein demonstrate that after a single neonatal i.v. dose of helperdependent adenovirus expressing FVIII, long-term low-level expression with alteration of the phenotype is possible; furthermore, this expression is not associated with evidence of acute toxicity or an innate inflammatory response related to the vector capsid that occurs when adenoviral vectors have been administered to both large (40, 41) and small animals (42, 43) .
Although expression is high within 3 d of injection, a rapid decline occurs over the first 4 wk with stable expression of 3-7% thereafter to at least 16 mo. Subsequent augmentation of expression was possible with readministration of vector as the development of an immune response to FVIII protein (i.e., tolerance) and vector capsid (i.e., ignorance) was lacking. The early and rapid decline is not immune mediated; rather, episomal vector genome loss appears to be related to hepatocellular division resulting in (i) dilution of vector genomes in an expanding population of hepatocytes and (ii) likely by degradation of genomes by an as yet unknown mechanism. Furthermore, FVIII levels themselves decrease in part as the volume of blood greatly expands as animals increase in size from neonates to adults. Although it was not observed, there may be a risk associated with the very high levels of FVIII achieved in the early neonatal period. As demonstrated in adult patients, high FVIII levels are a risk factor for venous thrombosis (44) (45) (46) . Whereas the FVIII levels attained in this study were very high 3 d after vector administration (∼650% of normal), they rapidly declined to ∼135% of normal by day 18. As elevated plasma FVIII levels are a dose-dependent risk , factor VIII deficient (hemophilic); Hd-AV, neonatal helper-dependent adenovirus injected; wks, weeks; mos, months.] (n ≥ 4 animals per group.) Fig. 4 . Viral copy number in liver was measured at selected time points by quantitative PCR. Viral copy number was measured shortly after injection on DOL3 until animals were ≥1 y of age (DOL, day of life; wks, weeks; mos, months; yr, year.) (n ≥ 3 animals at each time point.)
factor for primary and recurrent venous thromboembolism in adults (45) , attention to the potential risk of thrombophilia would need to be considered if such a therapy in humans is adopted in a future clinical investigation.
The goal of gene therapy for hemophilia A has been to safely and stably achieve levels of FVIII activity at ≥5% (47) to convert severe hemophilia to a milder form of the disease. These studies demonstrate that this is achievable with therapy beginning in the early neonatal period in mice. However, it is possible that these modest levels will not be sufficient to prevent catastrophic bleeding with more severe injury. These studies demonstrate that the successful induction of operational tolerance that a single additional vector administration after adult size has been attained can be performed for sustained augmented expression. Furthermore it is likely that supplemental doses of recombinant FVIII could be administered to transiently augment endogenous vector-mediated expression once operational tolerance has been established.
Tolerance has been induced exclusively to the FVIII protein and not to the viral capsid antigens as helper-dependent adenoviral vectors are replication incompetent without viral coding genes, thus preserving the ability for protective immune responses to potential future exposures to adenoviral pathogens. A number of studies have demonstrated that early persistent antigen presentation is required to maintain tolerance (48) (49) (50) and it is likely that initiating FVIII expression during this immunologically critical period makes FVIII tolerance possible. Although viral uncoating occurs during a time of immune immaturity resulting in lack of an immune response, it does not result in operational tolerance to vectorassociated antigens as there is no persistence of viral protein unlike the transgene protein FVIII. Instead the second dose of vector administered as an adult results in the expected primary immune response. This is not an anamnestic response to vector-associated antigens; immunological ignorance, not tolerance, was the mechanism of initial unresponsiveness to vector. Establishing tolerance to FVIII results in lack of inhibitory antibody development and thus makes augmentation of expression possible. Further safety of this therapeutic approach of neonatal gene therapy may be achieved by considering a vector system such as adeno-associated virus where there is no known human pathogenicity in the chance that tolerance was established to the vector antigens.
These studies report that inhibitors in hemophilia A, where clinically their development can affect therapy in up to 25% of patients, can be prevented in a small animal model by using gene replacement strategies to induce operational tolerance by the administration of helper-dependent adenoviral vector expressing FVIII shortly after birth. Furthermore, a single dose leads to longterm FVIII expression and phenotypic alteration without loss of protective immunity to adenovirus.
Materials and Methods
Generation of Helper-Dependent Adenoviral Vectors. A helper-dependent adenoviral vector (Hd-AV-FVIII) was generated with a liver-specific (PEPCK) promoter, ApoAI intron, and carrying the B domain-deleted human factor VIII cDNA and WPRE to increase expression. B domain-deleted hFVIII cDNA was cloned into pPEPCK vector downstream of the PEPCK promoter and upstream of the WPRE element to generate pPEPCK-hFVIII. This plasmid was then enzymatically digested with AscI and the insert containing the PEPCK promoter, hFVIII ORF, and the WPRE was subcloned into pD28E4 to produce pD28E4-mAI (Fig. 1) . The LacZ cDNA was cloned into the NotI site of the pPEPCK plasmid. The PEPCK-LacZ expression cassette was digested with AscI and inserted into the pD21.7E4 plasmid (51) .
Hd-AV-PEPCK-hFVIII-WPRE and Hd-AV-PEPCK-LacZ-WPRE were produced using the helper virus AdNG163R-2(52) and 116 producer cells as described in detail elsewhere (52, 53) . The Hd-AV vectors were purified by triple CsCl ultracentrifugation and formulated in 10 mM Tris-HCl, pH 8.0, supplemented with glycerol to 10%. Virion DNA was extracted for analysis by Southern blot hybridization and the levels of helper virus contamination determined by phosphorimager analysis were found to be <0.05% for both vector preparations. Physical vector titer was determined spectrophotometrically and expressed as vp per milliliter as described in detail elsewhere (54) . Mice and Animal Procedures. FVIII exon 16 knockout hemophilia A mice, purchased from The Jackson Laboratory, were used in all of the experiments described in this study. The characteristics of the exon-16 strains of hemophilic mice have been previously reported (55, 56) and were backcrossed with FVB/n mice (Charles River) through 10 cycles before these studies. The immune characteristics of these mice to human FVIII have been described (32) . All mice were housed under specific pathogen-free conditions; food and water were provided ad libitum. All experimental procedures were conducted in accordance with institutional guidelines for animal care and use. Newborn pups on the third day of life and adult mice at 2 mo of age from X H X H and X H Y matings were injected with Hd-AV-FVIII diluted in pharmaceutical grade saline (5 × 10 12 viral particles/kg) in the superficial temporal vein or by tail vein injection, respectively. The injections were performed with a total volume of 40 μL in pups and 200 μL in adults. Males and females were equally represented throughout the study. When mice were killed, the livers were harvested and kept at −80°C until analysis. After the vector injection, the mice were bled by retro-orbital or venous bleeding. Plasma was frozen immediately and stored at −80°C until analysis.
Assays for Human Factor VIII Expression and Phenotypic Correction. Plasma used for assay of human FVIII was collected at regular intervals from bleeding using heparinized tubes. FVIII expression was quantitated by an ELISA specific for the human protein. FVIII standards were generated using pooled normal human plasma (Sigma-Aldrich). Detection was performed according to the manufacturer's instructions (Enzyme Research Laboratories). Phenotypic correction was assessed by tail transection bleeding time as described (57) . The mouse tail was transected at 5 mm from the tip and was immediately immersed into 37°C saline. The bleeding time was determined as the time from the tail transection to the moment the blood flow stopped for >60 s. Bleeding time beyond 600 s was considered cutoff time for the purpose of analysis.
Examination of Immune Responses to Adenovirus and Human Factor VIII After Viral or Recombinant FVIII Injection. Immune response to capsid protein was measured by anti-adenovirus ELISA. Ninety-six-well immunoplates (NUNC) were coated with 1 × 10 8 viral particles/well of Hd-AV-LacZ that were prepared in 75 μL of 50 mM carbonate buffer (pH 9.6). To inactivate the virus, the plates were exposed to UV light for 30 min. Following an overnight incubation at 4°C and washing with PBS, 200 μL of blocking reagent (PBS with 5% FCS) was added to each well and incubated at 37°C for 2 h. Meanwhile, twofold dilutions of plasma samples from experimental and control groups, beginning from 1:40, were prepared in 1% BSA/PBST. After the plates were washed, 100 μL of diluted plasma was added in duplicate and subsequently incubated for 2 h at 37°C. Fifty microliters of 1:1,000 dilution of HRP-conjugated goat-anti-mouse secondary antibody (BD Pharmingen) was added and incubated for 1 h at 37°C. The plates were washed as above and incubated with 50 μL of o-phenylenediamine dihydrochloride substrate for up to 6 min. Color development was stopped by adding 50 μL of 2.5 M sulfuric acid and was measured for absorbance at 492 nm; background was defined as the absorbance measured in the absence of primary and secondary antibody. The anti-human FVIII ELISA was similarly performed except the sample volume was 50 μL/well. The immunoplates were initially coated with 0.122 IU/well of B domain-deleted human recombinant FVIII (Xyntha; Pfizer). A positive control anti-adenovirus antibody was generated by intraperitoneally administering a naive 8-wkold adult mouse with 5 × 10 10 vp of Hd-AV-LacZ mixed with Alum (Pierce).
Blood was collected 4 wk later and serum was removed and stored at −80°C until needed. A mouse anti-human FVIII antibody was generated by injecting an adult mouse i.v. with Hd-AV-FVIII.
Determination of Serum ALT. Blood was collected from mice at 35 d of life and analyzed as described (IDEXX Veterinary Services) with results pooled and mean and SD calculated.
Vector Copy Number Analysis. At regular intervals, mice were killed and liver tissue was removed. Genomic DNA was extracted (DNAEasy Kit; Qiagen) and quantitated by nanodrop (ND-1000 spectrophotometer; NanoDrop Technologies). Using real-time quantitative PCR (MyIQ2; Bio-Rad Laboratories) of the hGH poly(A) signal (forward primer, 5′AATCTTGGCTCACTGCAATCTCCG3′; reverse primer, 5′CATGCATGCCTGGAATCCCAACAA3′) with SsoFast EvaGreen detection (Bio-Rad Laboratories), quantification of vector genomes was determined in duplicate. The PCR product size was 89 bp, amplified by the following conditions: 98°C for 5 s and 60°C for 10 s for 33 cycles in 96-well plates (plates and TempPlate RT Optical film were both from USA Scientific) as described above using 1 μL of DNA per reaction as template (reaction volume, 15 μL; final primer concentration, 333 nM). The efficiency of this PCR is 107.3%, R 2 = 0.998. A value of 150 vector particles/1 ng was used for vector copy number determination. Liver tissue from saline-injected mice (n = 3) at each time point was used for nontemplate controls and demonstrated no amplification. Determination of copy numbers was based on known of dilutions of plasmid pAAV-CBA-OVA-hGHpa.
Statistical Analysis. Statistical calculations were performed using the SPSS version 17.0 statistical software package. Statistical significance was determined by paired t test with P value set at ≤0.05. Data are presented as mean ± SD unless stated otherwise.
